For research use only · Not for human consumption
This material is reference information for laboratory study of research peptides. It is not medical advice and it is not instructions for human use, self-administration, or therapeutic application. Capital Peptides supplies research chemicals for in-vitro and animal-model study only. Discuss any health-related questions with a licensed medical practitioner.
1. When to consider adjusting
| Scenario | Likely adjustment |
|---|---|
| Side effects are persistent beyond week 3 | Reduce dose 25–30% |
| No results at week 4 despite consistency | Check dosing maths first; consider increasing dose to upper end of range |
| Results plateaued mid-cycle | Consider dose increase or adding a synergistic compound if appropriate |
| Life event requires pausing (travel, illness, surgery) | Planned pause — see pausing section |
| New symptom that may be related to the peptide | Pause, assess, restart at lower dose once resolved |
| Out of supply — unable to restock in time | Managed taper or pause — see running out guide |
2. Changing the dose
Whether reducing (for side effects) or increasing (for efficacy), change dose gradually — not in one large step:
- Reducing dose: Drop 25–30% from current dose. Wait 10–14 days. If side effects resolve, continue at the lower dose. If they don't resolve adequately, reduce another 25% or consider stopping the cycle early.
- Increasing dose: Increase by 25% at a time. Wait at least 10–14 days between increases. Never exceed the upper end of the documented dose range — above this range, side effects increase without corresponding benefit for most peptides.
- Frequency changes: Adjusting from twice daily to once daily (or vice versa) counts as a dose change. Allow the same assessment window.
3. Pausing the protocol
Short pauses (up to 2 weeks) mid-cycle are generally not cycle-ending. Here's what to expect:
| Pause duration | Impact | Restart approach |
|---|---|---|
| 1–5 days | Minimal — results not lost | Resume normal dose as if no interruption |
| 1–2 weeks | Modest setback — some GH pulse patterns reset | Resume at current dose; may need 1–2 weeks to return to prior state |
| 2–4 weeks | Significant — effectively restart sensitivities | Restart at 75% of previous dose, escalate over 1–2 weeks |
| 4+ weeks | Full cycle restart | Begin a new cycle from starting dose |
For healing peptide protocols: a short pause during an acute illness is sensible — your immune system is already taxed. Resume when recovered.
4. Switching compounds mid-cycle
Switching compounds mid-cycle is generally not recommended unless there's a specific reason (intolerance, supply issue, new goal). If you do switch:
- Allow 3–5 days washout from the original compound before starting the new one, unless they have different mechanisms and no interaction risk.
- Start the new compound at the low end of its dose range, as you would in a fresh cycle.
- Consider this the start of a new cycle for tracking purposes — don't carry over the timing from the previous compound.
5. Stopping early
Valid reasons to stop a cycle before the planned endpoint:
- Red-flag symptoms (see the side effect calendar)
- New medical diagnosis that changes your risk profile
- Side effects that don't resolve with two dose reductions
- Goal achieved (e.g., injury healed) and there's no benefit to continuing
For most research peptides, there is no tapering requirement when stopping — you can stop cold. The exception is if you've been on a GLP-1 agonist for an extended period at high doses — some clinicians recommend a brief step-down to avoid rebound hunger/appetite effects, though this is not well-studied in research settings.